JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins for use in life sciences, food and nutrition, and industrial biotechnology applications utilizing its proprietary gene expression platforms, today announced that it will report its financial results for the sec ...

Core Insights - REGENXBIO Inc. will host a conference call on November 6, 2025, at 8:00 a.m. ET to discuss its Q3 financial results and operational highlights [1][2]. Company Overview - REGENXBIO is a biotechnology company focused on gene therapy, founded in 2009, and has pioneered AAV gene therapy [3]. - The company is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for Duchenne, clemidsogene lanparvovec (RGX-121) for MPS II, and RGX-111 for MPS I, in partnership with Nippon Shinyaku [3]. - REGENXBIO is also collaborating with AbbVie on surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy [3]. - Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® [3]. - The investigational gene therapies have the potential to significantly impact healthcare delivery for millions [3].

NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial results from the third quarter of 2025 and provide a corporate update during a live webcast on Wednesday, November 5, 2025 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcas ...

Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infectionsCAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership accelerating antibacterial products to address drug-resistant b ...

Accessibility StatementSkip Navigation ZURICH, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes today announced that the ITOL-102 cell therapy program for Type 1 Diabetes, originally ...

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S. financial markets. The company does not intend to hold a conference call. About Tango TherapeuticsTango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using ...

Oct 29, 2025 6:30 AM Eastern Daylight Time Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors Share LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a par ...

Core Insights - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [1] - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [1] - The company is participating in several industry and investor conferences in November, including BIO-Europe and the Jefferies Global Healthcare Conference [3] Company Overview - Immunic, Inc. is listed on Nasdaq under the ticker IMUX and specializes in therapies for chronic inflammatory and autoimmune diseases [1] - Vidofludimus calcium acts as a first-in-class nuclear receptor-related 1 (Nurr1) activator and selectively inhibits dihydroorotate dehydrogenase (DHODH) [1] - Other development programs include IMU-856, targeting Sirtuin 6 (SIRT6) for gastrointestinal diseases, and IMU-381, currently in preclinical testing [1] Clinical Development - Vidofludimus calcium has shown therapeutic activity in phase 2 trials for relapsing-remitting and progressive multiple sclerosis [1] - IMU-856 aims to restore intestinal barrier function and could be applicable in various gastrointestinal diseases [1] - IMU-381 is being developed to address specific needs in gastrointestinal diseases and is currently in preclinical testing [1]

Accessibility StatementSkip Navigation The new CUSIP number for the Common Shares following the Merger and the Reverse Split will be H5835A109. A notice of the Reverse Split and other capital measures approved by the Company in connection with the Merger and the Reverse Split, will be filed with the commercial registry of the Canton of Zurich, Switzerland, on October 30, 2025. As a result, the Reverse Split will become effective in Switzerland on October 30, 2025, and will be reflected on Nasdaq at market o ...

Core Insights - In September, the OTC market in the U.S. welcomed 30 new companies, a decrease of 9 compared to the previous month [1] - There were 5 companies that transitioned from OTC to the main board, an increase of 3 from August [1] - The new listings came from 6 countries, with Canada accounting for 47% of the new companies [1] - As of September 30, 2025, there are 12,278 companies listed on the U.S. OTC market, with a transaction volume of $61.2 billion for the month and $527.1 billion year-to-date [1] New Listings - The following companies were newly listed in September: - EMPIRE METALS LTD (OTCQX: EPMLF) - VERUSA HOLDING A S (OTCQX: VRSHF) - ACG Metals Limited (OTCQX: ACGAF) - FIRST NORDIC METALS CORP. (OTCQX: FNMCF) - Bitcoin Treasury Corporation (OTCQX: BTCFF) - Radisson Mining Resources Inc. (OTCQX: RMRDF) - Bonvenu Bancorp, Inc. (OTCQX: BBNA) - Associated Capital Group, Inc. (OTCQX: ACGP) - Horizon Kinetics Holding Corporation (OTCQX: HKHC) - Capstone Green Energy Holdings Inc. (OTCQX: CGEH) - Pacifica Silver Corp. (OTCQB: PAGFF) - BIONXT SOLUTIONS INC. (OTCQB: BNXTF) - Metalsource Mining Inc. (OTCQB: SFRIF) - Orogen Royalties Inc (OTCQB: OGNNF) - SUPERQ QUANTUM COMPUTING INC (OTCQB: QBTQF) - WESTERN STAR RES INC. (OTCQB: WSRIF) - Top End Energy Limited (OTCQB: SERPY, TNDEF) - Hamak Gold Limited (OTCQB: HASTF) - IMA TECH (OTCQB: IMAA) - TOKENWELL PLATFORMS INC. (OTCQB: TWELF) - Crypto Blockchain Industries, SA (OTCQB: CBIPF) - GREENLAND RES INC. (OTCQB: GRLRF) - Nexcel Metals Corp. (OTCQB: NXXCF) - Atex Resources Inc. (OTCQB: ATXRF) - Longevity Health Holdings, Inc. (OTCQB: XAGE) - PRINCE SILVER CORP (OTCQB: PRNCF) - Grayscale Near Trust (OTCQB: GSNR) - ConnectM Technology Solutions, Inc. (OTCQB: CNTM) - Eco Bright Future, Inc. (OTCQB: EBFI) - dMY Squared Technology Group, Inc. (OTCQB: DMYY, DMYYW) [1] Companies Transitioning to Main Board - Sono Group N.V. transitioned to NASDAQ with the ticker SSM on September 5, 2025, focusing on solar technology development and applications [2] - Sol Strategies, Inc. transitioned to NASDAQ with the ticker STKE on September 9, 2025, specializing in Solana blockchain infrastructure [3] - Spruce Biosciences, Inc. transitioned to NASDAQ with the ticker SPRB on September 15, 2025, focusing on innovative therapies for rare endocrine diseases [7] - Grayscale transitioned to NYSE MKT with the ticker GDLC on September 19, 2025, as a multi-asset cryptocurrency fund [8] - BTQ Technologies Corp. transitioned to NASDAQ with the ticker BTQ on September 26, 2025, focusing on quantum computing and cybersecurity [8]